Vitrolife Past Earnings Performance

Past criteria checks 0/6

Vitrolife's earnings have been declining at an average annual rate of -39.9%, while the Biotechs industry saw earnings declining at 1.4% annually. Revenues have been growing at an average rate of 25.8% per year.

Key information

-39.9%

Earnings growth rate

-39.8%

EPS growth rate

Biotechs Industry Growth0.7%
Revenue growth rate25.8%
Return on equity-30.3%
Net Margin-109.7%
Next Earnings Update18 Apr 2024

Recent past performance updates

Recent updates

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Aug 25
An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Vitrolife (STO:VITR) Could Easily Take On More Debt

Aug 03
Vitrolife (STO:VITR) Could Easily Take On More Debt

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

May 26
Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

Is Vitrolife (STO:VITR) A Risky Investment?

Jan 23
Is Vitrolife (STO:VITR) A Risky Investment?

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Oct 18
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Sep 09
Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Jul 07
Is Vitrolife (STO:VITR) A Risky Investment?

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

May 26
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Mar 31
Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Feb 07
Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

There May Be Reason For Hope In Vitrolife's (STO:VITR) Disappointing Earnings

Apr 29
There May Be Reason For Hope In Vitrolife's (STO:VITR) Disappointing Earnings

Is Vitrolife AB (publ)'s (STO:VITR) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Mar 16
Is Vitrolife AB (publ)'s (STO:VITR) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Who Has Been Selling Vitrolife AB (publ) (STO:VITR) Shares?

Jan 22
Who Has Been Selling Vitrolife AB (publ) (STO:VITR) Shares?

Vitrolife (STO:VITR) Shareholders Have Enjoyed An Impressive 289% Share Price Gain

Dec 18
Vitrolife (STO:VITR) Shareholders Have Enjoyed An Impressive 289% Share Price Gain

Revenue & Expenses Breakdown
Beta

How Vitrolife makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:VITR Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 233,512-3,8511,117127
30 Sep 233,4624021,092122
30 Jun 233,4123881,076124
31 Mar 233,3364121,048133
31 Dec 223,2343941,002143
30 Sep 222,893353961157
30 Jun 222,501349811151
31 Mar 222,054305656133
31 Dec 211,681341503114
30 Sep 211,549415353103
30 Jun 211,46439933394
31 Mar 211,29132530891
31 Dec 201,24628731192
30 Sep 201,27327632497
30 Jun 201,331294342102
31 Mar 201,502377365105
31 Dec 191,480383351100
30 Sep 191,39137134288
30 Jun 191,29733931880
31 Mar 191,19932429374
31 Dec 181,15131028472
30 Sep 181,10229427870
30 Jun 181,06428427670
31 Mar 181,06627627669
31 Dec 171,04626427069
30 Sep 171,02625526671
30 Jun 1799123426270
31 Mar 1791321125468
31 Dec 1685619025062
30 Sep 1680418823555
30 Jun 1677119623155
31 Mar 1674718622353
31 Dec 1572218322056
30 Sep 1566015421356
30 Jun 1560913719548
31 Mar 1555412218645
31 Dec 1451110917242
30 Sep 144979616852
30 Jun 144817716658
31 Mar 144676716559
31 Dec 134535616459
30 Sep 134274116249
30 Jun 134013215744
31 Mar 133813115242

Quality Earnings: VITR is currently unprofitable.

Growing Profit Margin: VITR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VITR is unprofitable, and losses have increased over the past 5 years at a rate of 39.9% per year.

Accelerating Growth: Unable to compare VITR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VITR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).


Return on Equity

High ROE: VITR has a negative Return on Equity (-30.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.